LC-MS/MS quantification of levetiracetam, lamotrigine and 10-hydroxycarbazepine in TDM of epileptic patients

Biomed Chromatogr. 2022 Aug;36(8):e5393. doi: 10.1002/bmc.5393. Epub 2022 May 18.

Abstract

Background: To minimize drug-related toxicity and monitor dosing regimens, an ultra-sensitive, simple and high-throughput analytical method for therapeutic drug monitoring is required. A novel LC-MS/MS bioassay of levetiracetam, lamotrigine and 10-hydroxycarbazepine in human plasma was established. The analytes were separated on a Hypersil GOLD™ C18 column under a 2.5 min isocratic elution after one-step protein precipitation. MS detection was performed under electrospray ionization positive-mode fitted with selected reaction monitoring. The validated ranges were 0.1-20 μg/ml for LTG, 0.3-60 μg/ml for 10-hydroxycarbazepine and levetiracetam. The intra- and inter-batches of precision and accuracy was within ±15%. The novel method met all other criteria.

Conclusion: This method can be used to monitor drug concentrations and decision-making in epileptic patients.

Keywords: 10-hydroxycarbazepine; LC-MS/MS; epileptic patients; lamotrigine; levetiracetam; therapeutic drug monitoring.

MeSH terms

  • Anticonvulsants
  • Carbamazepine / analogs & derivatives
  • Chromatography, High Pressure Liquid / methods
  • Chromatography, Liquid
  • Drug Monitoring / methods
  • Epilepsy* / drug therapy
  • Humans
  • Lamotrigine / therapeutic use
  • Levetiracetam
  • Reproducibility of Results
  • Tandem Mass Spectrometry* / methods

Substances

  • 10,11-dihydro-10-hydroxycarbamazepine
  • Anticonvulsants
  • Carbamazepine
  • Levetiracetam
  • Lamotrigine